Gaps in MASLD/MASH Education: A Quantitative and Qualitative Survey with Leaders of US Graduate Medical Education Programs

Alina M Allen,1 Anthony R Hoovler,2 Amy Articolo,3 Travis Fisher,4 Mazen Noureddin,5 Douglas Dieterich6 1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA; 2Liver Health, Novo Nordisk Inc., Plainsboro, NJ, USA; 3Global Medical Affairs, Novo Nordisk Inc., Plainsboro, NJ, US...

Full description

Saved in:
Bibliographic Details
Main Authors: Allen AM, Hoovler AR, Articolo A, Fisher T, Noureddin M, Dieterich D
Format: Article
Language:English
Published: Dove Medical Press 2025-05-01
Series:Advances in Medical Education and Practice
Subjects:
Online Access:https://www.dovepress.com/gaps-in-masldmash-education-a-quantitative-and-qualitative-survey-with-peer-reviewed-fulltext-article-AMEP
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849728509093609472
author Allen AM
Hoovler AR
Articolo A
Fisher T
Noureddin M
Dieterich D
author_facet Allen AM
Hoovler AR
Articolo A
Fisher T
Noureddin M
Dieterich D
author_sort Allen AM
collection DOAJ
description Alina M Allen,1 Anthony R Hoovler,2 Amy Articolo,3 Travis Fisher,4 Mazen Noureddin,5 Douglas Dieterich6 1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA; 2Liver Health, Novo Nordisk Inc., Plainsboro, NJ, USA; 3Global Medical Affairs, Novo Nordisk Inc., Plainsboro, NJ, USA; 4US Medical Affairs, Novo Nordisk Inc., Plainsboro, NJ, USA; 5Department of Medicine, Houston Methodist Hospital, and Houston Research Institute, Houston, TX, USA; 6Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USACorrespondence: Alina M Allen, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA, Tel +1 507 284 3917, Email allen.alina@mayo.eduPurpose: Metabolic dysfunction–associated steatotic liver disease (MASLD) and its inflammatory subtype, metabolic dysfunction–associated steatohepatitis (MASH), are associated with cardiometabolic risk factors, including obesity and type 2 diabetes. The prevalence of both conditions is rising rapidly and is underdiagnosed (< 5%). We aimed to gather qualitative and quantitative insights from program leaders in US medical education training on their experience with MASH-related training and education.Participants and methods: A cross-sectional study consisting of a quantitative survey and qualitative discussions with individuals in primary care (internal medicine and family medicine) and specialty programs (hepatology, gastroenterology, and endocrinology) were held from February 21 to August 28, 2023. Descriptive statistics were used for data analysis.Results: A total of 190 leaders participated in the online survey and 11 leaders joined the focus groups. Almost all respondents reported that MASLD (96%) and MASH (92%) were included in their program’s curricula. However, many believed that little time was devoted to discussing MASH in their program. Most respondents agreed that MASH is extremely underdiagnosed. Program leaders agreed that the interconnectedness of MASH with other cardiometabolic conditions necessitates instruction time on MASH beyond that of its dedicated curriculum time. All participants believed that emergence of regulatory-approved drugs for MASH will drive a decision to increase the time allotted for MASH in the curriculum.Conclusion: Although program leaders agreed that MASH has an important place in medical education curricula, the relative paucity of treatment options reduces its coverage in training, thereby limiting healthcare practitioners’ understanding of MASH.Plain Language Summary: Metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH) are liver conditions that often appear with obesity and type 2 diabetes. Despite the high prevalence and increasing impact of MASLD and MASH, the majority of affected patients are not diagnosed and present late in the course of disease. These observations suggest limits in awareness. This study aimed to understand how US healthcare providers (HCPs) felt about the level of attention MASLD and MASH receive in medical education training programs. An online survey (N = 190) and focus group discussions (N = 11) were held with people who were familiar with their program’s education and training. Most participants said that MASH is often not diagnosed, which can lead to problems; however, it is important to include it in the school’s curriculum. Many people said they think MASH is connected to other conditions, and that meant that HCPs were being trained on it indirectly. Once a treatment for MASH is approved, most participants believed MASH will be covered more in their education programs. Even though MASH is thought to have an important place in the training of HCPs, program leaders saw limited treatment options as a barrier to having more focused time spent on it in their educational programs. Keywords: nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, education, medical, curriculum, surveys and questionnaires, focus groups
format Article
id doaj-art-cfbd6dca0ef742b1abe6cf52a762b5d3
institution DOAJ
issn 1179-7258
language English
publishDate 2025-05-01
publisher Dove Medical Press
record_format Article
series Advances in Medical Education and Practice
spelling doaj-art-cfbd6dca0ef742b1abe6cf52a762b5d32025-08-20T03:09:32ZengDove Medical PressAdvances in Medical Education and Practice1179-72582025-05-01Volume 16Issue 1729748102659Gaps in MASLD/MASH Education: A Quantitative and Qualitative Survey with Leaders of US Graduate Medical Education ProgramsAllen AM0Hoovler AR1Articolo A2Fisher TNoureddin MDieterich D3Division of Gastroenterology and HepatologyMedical Affairs, Liver HealthGlobal Medical AffairsDivision of Liver Diseases, Department of MedicineAlina M Allen,1 Anthony R Hoovler,2 Amy Articolo,3 Travis Fisher,4 Mazen Noureddin,5 Douglas Dieterich6 1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA; 2Liver Health, Novo Nordisk Inc., Plainsboro, NJ, USA; 3Global Medical Affairs, Novo Nordisk Inc., Plainsboro, NJ, USA; 4US Medical Affairs, Novo Nordisk Inc., Plainsboro, NJ, USA; 5Department of Medicine, Houston Methodist Hospital, and Houston Research Institute, Houston, TX, USA; 6Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USACorrespondence: Alina M Allen, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA, Tel +1 507 284 3917, Email allen.alina@mayo.eduPurpose: Metabolic dysfunction–associated steatotic liver disease (MASLD) and its inflammatory subtype, metabolic dysfunction–associated steatohepatitis (MASH), are associated with cardiometabolic risk factors, including obesity and type 2 diabetes. The prevalence of both conditions is rising rapidly and is underdiagnosed (< 5%). We aimed to gather qualitative and quantitative insights from program leaders in US medical education training on their experience with MASH-related training and education.Participants and methods: A cross-sectional study consisting of a quantitative survey and qualitative discussions with individuals in primary care (internal medicine and family medicine) and specialty programs (hepatology, gastroenterology, and endocrinology) were held from February 21 to August 28, 2023. Descriptive statistics were used for data analysis.Results: A total of 190 leaders participated in the online survey and 11 leaders joined the focus groups. Almost all respondents reported that MASLD (96%) and MASH (92%) were included in their program’s curricula. However, many believed that little time was devoted to discussing MASH in their program. Most respondents agreed that MASH is extremely underdiagnosed. Program leaders agreed that the interconnectedness of MASH with other cardiometabolic conditions necessitates instruction time on MASH beyond that of its dedicated curriculum time. All participants believed that emergence of regulatory-approved drugs for MASH will drive a decision to increase the time allotted for MASH in the curriculum.Conclusion: Although program leaders agreed that MASH has an important place in medical education curricula, the relative paucity of treatment options reduces its coverage in training, thereby limiting healthcare practitioners’ understanding of MASH.Plain Language Summary: Metabolic dysfunction–associated steatotic liver disease (MASLD) and metabolic dysfunction–associated steatohepatitis (MASH) are liver conditions that often appear with obesity and type 2 diabetes. Despite the high prevalence and increasing impact of MASLD and MASH, the majority of affected patients are not diagnosed and present late in the course of disease. These observations suggest limits in awareness. This study aimed to understand how US healthcare providers (HCPs) felt about the level of attention MASLD and MASH receive in medical education training programs. An online survey (N = 190) and focus group discussions (N = 11) were held with people who were familiar with their program’s education and training. Most participants said that MASH is often not diagnosed, which can lead to problems; however, it is important to include it in the school’s curriculum. Many people said they think MASH is connected to other conditions, and that meant that HCPs were being trained on it indirectly. Once a treatment for MASH is approved, most participants believed MASH will be covered more in their education programs. Even though MASH is thought to have an important place in the training of HCPs, program leaders saw limited treatment options as a barrier to having more focused time spent on it in their educational programs. Keywords: nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, education, medical, curriculum, surveys and questionnaires, focus groupshttps://www.dovepress.com/gaps-in-masldmash-education-a-quantitative-and-qualitative-survey-with-peer-reviewed-fulltext-article-AMEPnonalcoholic fatty liver diseasenonalcoholic steatohepatitiseducationmedicalcurriculumsurveys and questionnaires
spellingShingle Allen AM
Hoovler AR
Articolo A
Fisher T
Noureddin M
Dieterich D
Gaps in MASLD/MASH Education: A Quantitative and Qualitative Survey with Leaders of US Graduate Medical Education Programs
Advances in Medical Education and Practice
nonalcoholic fatty liver disease
nonalcoholic steatohepatitis
education
medical
curriculum
surveys and questionnaires
title Gaps in MASLD/MASH Education: A Quantitative and Qualitative Survey with Leaders of US Graduate Medical Education Programs
title_full Gaps in MASLD/MASH Education: A Quantitative and Qualitative Survey with Leaders of US Graduate Medical Education Programs
title_fullStr Gaps in MASLD/MASH Education: A Quantitative and Qualitative Survey with Leaders of US Graduate Medical Education Programs
title_full_unstemmed Gaps in MASLD/MASH Education: A Quantitative and Qualitative Survey with Leaders of US Graduate Medical Education Programs
title_short Gaps in MASLD/MASH Education: A Quantitative and Qualitative Survey with Leaders of US Graduate Medical Education Programs
title_sort gaps in masld mash education a quantitative and qualitative survey with leaders of us graduate medical education programs
topic nonalcoholic fatty liver disease
nonalcoholic steatohepatitis
education
medical
curriculum
surveys and questionnaires
url https://www.dovepress.com/gaps-in-masldmash-education-a-quantitative-and-qualitative-survey-with-peer-reviewed-fulltext-article-AMEP
work_keys_str_mv AT allenam gapsinmasldmasheducationaquantitativeandqualitativesurveywithleadersofusgraduatemedicaleducationprograms
AT hoovlerar gapsinmasldmasheducationaquantitativeandqualitativesurveywithleadersofusgraduatemedicaleducationprograms
AT articoloa gapsinmasldmasheducationaquantitativeandqualitativesurveywithleadersofusgraduatemedicaleducationprograms
AT fishert gapsinmasldmasheducationaquantitativeandqualitativesurveywithleadersofusgraduatemedicaleducationprograms
AT noureddinm gapsinmasldmasheducationaquantitativeandqualitativesurveywithleadersofusgraduatemedicaleducationprograms
AT dieterichd gapsinmasldmasheducationaquantitativeandqualitativesurveywithleadersofusgraduatemedicaleducationprograms